Steven C. Anderson, IOM, CAE

home / authors / steven-c-anderson-iom-cae

Articles

Students' Engagement Key to Making an Rximpact for Pharmacy

Students' Engagement Key to Making an Rximpact for Pharmacy

Steven C. Anderson, IOM, CAE
February 19th 2016

We know that the future of pharmacy rests in large part in the hands of pharmacy students.

Read More

Site Logo

Pharmacy Advocates Primed for the Future

Steven C. Anderson, IOM, CAE
September 15th 2009

Read More

Site Logo

Shaping the Future of Patient Care

Steven C. Anderson, IOM, CAE
September 1st 2008

Read More

Site Logo

CALLING ALL PHARMACISTS!

Steven C. Anderson, IOM, CAE
September 1st 2007

Mr. Anderson is president and chief executive officer at the National Association of Chain Drug Stores.

Read More

Site Logo

nacds SPEAKS OUT: Raising the Profile of Community Pharmacy

Steven C. Anderson, IOM, CAE
March 1st 2007

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD